A peptide certificate of analysis is a batch-specific report describing which analytical tests were performed on a material and what those tests found. For researchers comparing laboratory reagents, it is a starting point for checking identity, purity and suitability. The most useful question is not simply whether a certificate exists, but whether its results answer the requirements of your experiment.
This guide explains how to read a COA, distinguish different quality measurements and organise a procurement review. It does not certify any supplier or batch. Research materials should be evaluated within an institution’s approved procedures and intended laboratory use.
What should a peptide certificate of analysis contain?
Start with the document’s connection to the material in front of you. Look for a product identifier, a lot or batch number, a report date and the name of the organisation issuing the results. Where relevant, the specification should identify the peptide sequence, modifications and the form supplied. A familiar compound name alone may leave important details unresolved.
Next, separate the acceptance criteria from the measured results. A statement such as “specification: at least 98%” describes a target. A separate numerical result describes an observation. If the document only repeats a specification, ask whether testing was performed on the actual batch and whether the underlying report is available.
- Match the batch number on the report to the vial and order records.
- Check the identity test and the analytical method used.
- Identify what the purity percentage measures.
- Look for a separately stated content or assay result where your study requires it.
- Record any storage conditions and their supporting stability information.
- List tests that your application needs but the document does not report.
Identity, purity and content answer different questions
Identity asks whether the material is consistent with the intended substance. Purity describes impurities according to a defined test. Content concerns the amount of the target material in a sample. These concepts are related, but one number cannot replace all three.
A study on reference standards for synthetic peptide therapeutics describes the use of multiple analytical approaches to characterise standards and assign their values. Its central relevance for procurement is that a defensible assessment can require complementary measurements. A single headline percentage provides less information than a documented set of appropriate results.
Why chromatographic purity is not automatically peptide content
A chromatographic area percentage describes the relative detector response assigned to a peak under the stated method. It should not automatically be read as the percentage of the entire powder’s mass that is the target peptide. Water, counterions and other components may require separate measurements. Ask what basis the percentage uses before inserting it into an experimental calculation.
For a hypothetical example, imagine two reports both display 99% chromatographic purity. One also reports a content assay, while the other does not. The shared purity figure does not establish that equal weighed portions contain equal amounts of target material. Treat this as a documentation question rather than a reason to guess a correction factor.
How to review HPLC results
High-performance liquid chromatography separates components under selected conditions. A chromatogram typically plots detector response against time. To review it meaningfully, request enough method information to understand the reported result: the separation mode, detection conditions, integration approach and relevant acceptance criteria.
Check whether the report provides a chromatogram or only a summary. If there are additional peaks, ask how they were classified and whether the method can resolve the impurities relevant to your application. Avoid interpreting a visually tall main peak as a complete quality assessment.
Research on two-dimensional chromatography for peptide peak purity illustrates a specific limitation: structurally related impurities can coelute with a target peptide in a separation. Additional separation conditions can help investigate those components. This does not mean every purchase requires two-dimensional chromatography; it means the method’s resolving power matters when judging a purity claim.
Questions to ask about a chromatogram
- Does the sample identifier match the batch certificate?
- Are the axes and detection conditions labelled?
- Is the reported percentage based on a defined integration method?
- Were known relevant impurities considered?
- Is the method appropriate for this material and the question being asked?
What mass spectrometry can contribute
Mass spectrometry supplies complementary evidence about molecular characteristics. The published chapter on characterising synthetic peptides by mass spectrometry discusses its use in checking authenticity and integrity. Researchers should review an MS result alongside the stated molecular identity rather than treating it as interchangeable with a chromatographic purity measurement.
When reviewing a report, ask how the observed signal was assigned and whether the analytical strategy addresses the identity concerns of your study. A short label such as “MS passed” is less useful for independent assessment than a documented result with its interpretation. If sequence or structural confirmation is essential, ask the laboratory which evidence supports that requirement.
Use the COA to build an application-specific checklist
Before contacting a supplier, write down the decisions your experiment depends on. An analytical comparison, a cell-based assay and a reference-standard study may need different supporting evidence. This prevents the purchasing conversation from becoming a general debate about the largest purity number.
Create a short record with four columns: requirement, evidence supplied, unresolved question and decision owner. For example, the requirement may be confirmed batch identity; the evidence may be an MS report; the unresolved question may be an unclear sample identifier; and the decision owner may be your laboratory’s responsible researcher.
Do not mark a missing test as a pass. Record it as “not reported” and decide whether additional documentation or testing is needed. The distinction helps colleagues see what was actually measured and what remains an assumption.
Comparing suppliers without relying on marketing claims
Use consistent questions across shortlisted suppliers. Request batch-linked documentation, a clear explanation of reported values and a route for technical queries. Compare the completeness and relevance of the evidence before using price as the deciding factor. “Premium”, “laboratory grade” and similar descriptions do not explain a method or replace a result.
The VLS Peptide homepage provides a starting point for navigating the catalogue. Product descriptions are discovery information; they should be checked against the documentation for the actual batch under consideration. Avoid assuming that an article, product photograph or category label verifies a laboratory specification.
The same distinction applies to related research compounds. For example, the catalogue contains NAD+ 1000mg and Revion NAD+ 1000mg listings. NAD+ is a coenzyme rather than a peptide, so its analytical requirements should be assessed for that substance. Similar catalogue placement does not make different materials chemically equivalent.
Receiving and filing a research material
On receipt, compare the delivered identifiers with the purchase order and the reviewed certificate. Follow your laboratory’s handling procedures and the applicable documented conditions. If there is a discrepancy, separate the material from approved stock until the issue has been assessed by the responsible person.
Retain the original certificate, relevant technical correspondence, the receipt date and the internal inventory reference. When a new batch arrives, repeat the comparison rather than copying the previous batch’s approval. A reusable checklist saves effort while preserving the distinction between lots.
Frequently asked questions
1. Is a peptide certificate of analysis the same as independent testing?
No. A COA may be issued by a manufacturer, supplier or external laboratory. Read who performed the work, which sample was tested and which results are included. The existence of a certificate alone does not establish independent testing.
2. Does a 99% purity result establish suitability for every experiment?
No. Suitability depends on the test method, the material and the application’s requirements. Identity, content and other relevant characteristics may need separate evidence.
3. Why must the batch number match?
The number connects the report to a specific lot. A certificate for another batch may be informative about a supplier’s reporting format, but it does not document the delivered material.
4. Can a COA replace a full analytical report?
A summary can support routine review when it contains sufficient information. If your assessment requires chromatograms, spectra or additional method details, request those records rather than inferring them from the summary.
5. What should I do when information is missing?
List the missing items, ask specific technical questions and document the response. If the evidence remains inadequate for the intended study, refer the decision to the responsible researcher or quality lead before use.
A useful next step
Choose one batch under review and work through identity, reported purity, content where needed and traceability. Keep each conclusion tied to a documented result. That small discipline turns a certificate from a marketing attachment into a practical research record.